Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
Chinese biotech company Bliss Biopharmaceutical (BlissBio) is reportedly considering a Hong Kong initial public offering (IPO) that could raise at least $150 million, according to Bloomberg sources. The Hangzhou-based cancer drug developer is working with financial advisers to evaluate the listing, although final decisions have yet to be made and the IPO size could still change. There is also a possibility the company may postpone or cancel the plan.
Founded in 2017, BlissBio focuses on antibody-drug conjugates (ADCs) that specifically target tumors. The company currently has multiple therapies in early-stage clinical trials, including Phase 1 and Phase 2 studies, as stated on its website. ADCs are a cutting-edge treatment combining antibodies with cancer-killing agents to selectively target cancer cells, offering potential breakthroughs in oncology.
Investor interest in China's biotech sector remains strong, especially for innovative oncology firms. A recent example is Duality Biotherapeutics Inc (HK:9606), which saw its shares nearly double after its Hong Kong IPO last month, reflecting growing confidence in homegrown pharmaceutical innovation.
If successful, BlissBio’s IPO would join a wave of Chinese biotech listings on the Hong Kong Stock Exchange, which has become a favored venue for healthcare companies seeking capital to fund clinical trials and expand their R&D pipelines. With increasing demand for novel cancer therapies in China and globally, the market is watching closely to see whether BlissBio moves forward with the offering.
